Applikon to buy HaloteC’s biotech portfolio


Monday, 08 April, 2013

Bioreactor systems vendor Applikon Biotechnology has arranged to acquire the biotech portfolio of Dutch instruments and software provider HaloteC Instruments.

Applikon CEO Arthur Oudshoorn said the company plans to use the HaloteC technology to augment its existing its bioreactor software offerings.

“Organisations are looking for software solutions to allow parallel processing of bioreactor systems and to process the large amount of data generated by these processes,” he said.

Oudshoorn added that the investment forms part of Applikon’s efforts to be able to provide an advanced data centre for biotech processes.

Terms of the transaction were not disclosed.

Applikon Biotechnology is headquartered in the Netherlands and in Belgium. In Australia and New Zealand, the company provides its products through its dedicated agent Enztech in New South Wales.

Related News

Even non-antibiotics can disrupt the microbiome

Many non-antibiotics inhibit useful gut bacteria, giving rise to an imbalance in the microbiome,...

How brain stem cells move between resting and active states

Understanding this process is crucial, because it underpins how the brain repairs itself and...

Accurate age estimation with DNA methylation

Using cutting-edge artificial intelligence, scientists created a tool that can determine a...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd